Journal article icon

Journal article

Associations between demographic, clinical and dietary factors and flares in inflammatory bowel disease: the PRognostic effect of Environmental factors in Crohn’s and Colitis (PREdiCCt) prospective cohort study

Abstract:
Background: IBD is characterised by recurrent flares, but evidence on whether modifiable dietary factors influence flare risk is limited. Objective: The PREdiCCt study was designed to examine demographic, clinical and dietary factors associated with disease flare among patients with IBD in self-reported remission. Design: Multicentre, prospective cohort study conducted across 47 UK centres. Patients with Crohn’s disease (CD), ulcerative colitis (UC) or IBD unclassified (IBDU) in self-reported remission were prospectively followed up. The baseline diet was assessed using a validated food frequency questionnaire. The primary outcome was time to patient-reported flare (captured by monthly IBD-Control) and objective flare (clinical flare plus C-reactive protein >5 mg/L and/or faecal calprotectin (FC) >250 µg/g with treatment escalation). Associations were evaluated using Cox frailty models adjusted for demographic, clinical and biochemical variables, including baseline FC. Results: Between November 2016 and March 2020, 2629 participants (1370 CD; 1259 UC/IBDU) were enrolled and followed up for a median of 4.1 years (IQR 3.0–5.0). Baseline FC was strongly associated with patient-reported flares (FC ≥250 µg/g: adjusted HR (aHR) 2.22; FC 50–250 µg/g: aHR 1.52 (reference <50 µg/g)) and objective flares (FC ≥250 µg/g: aHR 3.25; FC 50–250 µg/g: aHR 1.98). In UC, higher total meat intake was associated with increased risk of objective flares (highest versus lowest quartile: aHR 1.95, 95% CI 1.07 to 3.56). No consistent associations were observed for ultraprocessed foods, fibre or polyunsaturated fatty acids and flare. Conclusion: Higher habitual meat intake was associated with increased risk of objective flare in UC, suggesting diet may contribute to flare susceptibility in specific patient groups. Trial registration number: NCT03282903.
Publication status:
Published
Peer review status:
Peer reviewed

Actions

Access Document

Publisher copy:
10.1136/gutjnl-2025-337846

Authors

More by this author
Role:
Author
ORCID:
0000-0002-4437-8713
More by this author
Role:
Author
ORCID:
0000-0002-3229-8759


More from this funder
Funder identifier:
https://ror.org/01613vh25
More from this funder
Funder identifier:
https://ror.org/001aqnf71


Publisher:
BMJ Publishing Group
Journal:
Gut More from this journal
Pages:
gutjnl-2025-337846
Article number:
gutjnl-2025-337846
Publication date:
2026-01-19
Acceptance date:
2025-12-31
DOI:
EISSN:
1468-3288
ISSN:
0017-5749


Language:
English
Keywords:
Pubs id:
2362663
UUID:
uuid_9d1cf940-363d-4a3d-8dcb-12301c636e17
Local pid:
pubs:2362663
Source identifiers:
3680966
Deposit date:
2026-01-21
ARK identifier:
This ORA record was generated from metadata provided by an external service. It has not been edited by the ORA Team.

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP